<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase I:  Off-the-Shelf immuno-compatible cell therapies</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>02/01/2021</AwardEffectiveDate>
<AwardExpirationDate>01/31/2022</AwardExpirationDate>
<AwardTotalIntnAmount>255750.00</AwardTotalIntnAmount>
<AwardAmount>255750</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Kaitlin Bratlie</SignBlockName>
<PO_EMAI>kbratlie@nsf.gov</PO_EMAI>
<PO_PHON>7032922638</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact of this Small Business Innovation Research (SBIR) Phase I project is to improve cell therapy by enabling the rapid development of novel and safe therapies through the seamless production of pre-characterized, good manufacturing practice (GMP) grade, universally immune-compatible induced pluripotent stem cell (iPSC) cell lines. The solution will target the global cell therapy market, expected to be the fastest-growing sector in the regenerative medicine industry and reaching $9.8 B by 2026. This project will advance a technology for better clinical trials. &lt;br/&gt;&lt;br/&gt;This Small Business Innovation Research (SBIR) Phase I project explores feasibility of a platform for the generation of completely immune-compatible Off-The-Shelf cell therapies. The platform employs a fully scalable workflow centered on master induced pluripotent cell lines engineered for universal immune-compatibility. Cells are further functionalized by site-specific insertion of bacterial integrase receiver sites enabling safe and reliable insertion of new DNA constructs into defined genomic loci with low risk for off-target events. This approach will produce immune-compatible iPSC Receiver Cells that can be differentiated into many different mature cell types for use in cell therapy applications. The proposed activities will validate a new approach to prevent host-versus-grafts rejections based on the disruption of chaperone proteins that impair major histocompatibility complex (MHC)-1 function without eliminating MHC-1 cell-surface expression. Several iPSC cell lines will be generated and tested in vitro and in vivo to investigate the efficacy of the proposed method to prevent HLA-dependent cytotoxic T cell “non-self” and NK cell “missing-self” responses. The ability of the generated iPSC to generate differentiated immune-compatible cell lines will be assessed, validating the entire workflow of the proposed platform.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>01/29/2021</MinAmdLetterDate>
<MaxAmdLetterDate>01/29/2021</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2036119</AwardID>
<Investigator>
<FirstName>Gary</FirstName>
<LastName>Sams</LastName>
<PI_MID_INIT>R</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Gary R Sams</PI_FULL_NAME>
<EmailAddress>SBIR2020@progenitorlifesciences.com</EmailAddress>
<PI_PHON>6198384882</PI_PHON>
<NSF_ID>000829819</NSF_ID>
<StartDate>01/29/2021</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>PROGENITOR INC.</Name>
<CityName>SALT LAKE CITY</CityName>
<ZipCode>841081228</ZipCode>
<PhoneNumber>6198384882</PhoneNumber>
<StreetAddress>675 S ARAPEEN DR STE 302</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>Utah</StateName>
<StateCode>UT</StateCode>
<CONGRESSDISTRICT>02</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>UT02</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>065800634</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>PROGENITOR INC.</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[PROGENITOR INC.]]></Name>
<CityName>SALT LAKE CITY</CityName>
<StateCode>UT</StateCode>
<ZipCode>841081228</ZipCode>
<StreetAddress><![CDATA[675 S ARAPEEN DR STE 302]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Utah</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>02</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>UT02</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>5371</Code>
<Text>SBIR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>6883</Code>
<Text>CHEMISTRY OF LIFE PROCESSES</Text>
</ProgramReference>
<Appropriation>
<Code>0121</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2021~255750</FUND_OBLG>
</Award>
</rootTag>
